Home > Insider Trading > Filing (0001104659-21-097601)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1831915	Cytek Biosciences Inc.	CTKB	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	200 Berkeley Street 18Th Floor Boston MA 02116	Yes	No	No	No
1346824	Ra Capital Management, L.p.	200 Berkeley Street 18Th Floor Boston MA 02116	Yes	No	No	No
1384859	Peter Kolchinsky	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	No	No
1619841	M. Rajeev Shah	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	No	No
1825376	Ra Capital Nexus Fund Ii, L.p.	200 Berkeley Street 18Th Floor Boston MA 02116	Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-07-27	5,150,751	$0.00	5,150,751	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2021-07-27	2,762,786	$17.00	7,913,537	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2021-07-27	998,553	$0.00	998,553	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2021-07-27	187,214	$17.00	1,185,767	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2021-07-27	507,724	$0.00	507,724	No	4	C	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	C	Indirect	See footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Preferred Stock	Disposition	2021-07-27	5,150,751	$0.00	5,150,751	$0.00
Common Stock	Series D Preferred Stock	Disposition	2021-07-27	998,553	$0.00	998,553	$0.00
Common Stock	Series D Preferred Stock	Disposition	2021-07-27	507,724	$0.00	507,724	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

On July 27, 2021, each share of Series D Preferred Stock (the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
These securities are held directly by a separately managed account (the "Account").
RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.